Pu-Yun OuYang

Dr. Pu-Yun OuYang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LZLu-Ning Zhang
Lu-Ning Zhang
YGYuanhong Gao
Yuanhong Gao
XLXiao-Wen Lan
Xiao-Wen Lan
JTJie Tang
Jie Tang
ZSZhen Su
Zhen Su
FXFang-Yun Xie
Fang-Yun Xie
Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era

12 October 2023 in Oral Oncology
Verified
Journal Article
Closed access
ZLZhi-Qiao Liu
Zhi-Qiao Liu
YZYa-Nan Zhao
Ya-Nan Zhao
YWYi-Shan Wu
Yi-Shan Wu
BZBao-Yu Zhang
Bao-Yu Zhang
ECEn-Ni Chen
En-Ni Chen
POPu-Yun OuYang
Pu-Yun OuYang

1 October 2015 in Oral Oncology
Verified
Journal Article
Open access
LZLu-Ning Zhang
Lu-Ning Zhang
YGYuanhong Gao
Yuanhong Gao
XLXiao-Wen Lan
Xiao-Wen Lan
JTJie Tang
Jie Tang
POPu-Yun OuYang
Pu-Yun OuYang
FXFang-Yun Xie
Fang-Yun Xie
The effect of taxanes-based induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC) was quite contradictory in two phase II randomized controlled trials with small sample size. We aimed to investigate it in this large scale propensity-matched study. Totally, 779 LA-NPC patients who underwent intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy with or without taxanes-based IC were included. Patients in both treatment arms were matched using propensity score matching method at the ratio of 1:1. Failure-free survival (FFS), overall survival (OS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRFS) were assessed with Kaplan-Meier method, log-rank test and Cox regression analysis. After matching, 534 patients were identified for analysis. In univariate analysis, both treatment arms resulted in parallel survival (4-years FFS 78.0% vs 74.1%, P = 0.304; OS 87.5% vs 87.3%, P = 0.595; DMFS 88.2% vs 84.4%, P = 0.154; and LRFS 91.2% vs 90.1%, P = 0.960). In multivariate analysis, taxanes-based IC did not improve any survival (P ⩾ 0.139). And this association remained unchanged in subgroup analysis by age, sex and histology, and among patients with stage III and T4N0M0. But among patients with T4N1-2M0 and stage IVb, taxanes-based IC significantly prolonged the 4-year DMFS by 11.2% (86.1% vs 74.9%, P = 0.034), and marginally improved FFS (P = 0.133) and OS (P = 0.215) in both univariate and multivariate analysis. In this large scale propensity-matched study, LA-NPC patients could not benefit from taxanes-based IC on the whole. But the risk of distant metastasis significantly decreased by above 10% for patients with T4N1-2M0 and stage IVb.

8 January 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
SYShan-Shan Yang
Shan-Shan Yang
JGJian-Gui Guo
Jian-Gui Guo
JLJia-Ni Liu
Jia-Ni Liu
ZLZhi-Qiao Liu
Zhi-Qiao Liu
ECEn-Ni Chen
En-Ni Chen
FXFang-Yun Xie
Fang-Yun Xie
Background: Previous meta-analysis had evaluated the effect of induction chemotherapy in nasopharyngeal carcinoma. But two trials with opposite findings were not included and the long-term result of another trial significantly differed from the preliminary report. This updated meta-analysis was thus warranted.Methods: Literature search was conducted to identify randomized controlled trials focusing on the additional efficacy of induction chemotherapy in nasopharyngeal carcinoma. Trial-level pooled analysis of hazard ratio (HR) for progression free survival and overall survival and risk ratio (RR) for locoregional control rate and distant control rate were performed.Results: Twelve trials were eligible. The addition of induction chemotherapy significantly prolonged both progression free survival (HR=0.68, 95% confidence interval [CI] 0.60–0.76, p<0.001) and overall survival (HR=0.67, 95% CI 0.54–0.80, p<0.001), with 5-year absolute benefit of 11.31% and 8.95%, respectively. Locoregional (RR=0.80, 95% CI 0.70–0.92, p=0.002) and distant control (RR=0.70, 95% CI 0.62–0.80) rates were significantly improved as well. The incidence of grade 3–4 adverse events during the concurrent chemoradiotherapy was higher in leukopenia (p=0.028), thrombocytopenia (p<0.001), and fatigue (p=0.038) in the induction chemotherapy group.Conclusions: This meta-analysis supported that induction chemotherapy could benefit patients with nasopharyngeal carcinoma in progression free survival, overall survival, locoregional, and distant control rate.

3 September 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
POPu-Yun OuYang
Pu-Yun OuYang
KYKai‐Yun You
Kai‐Yun You
LZLu‐Ning Zhang
Lu‐Ning Zhang
YXYao Xiao
Yao Xiao
XZXiaomin xiaomin OR xiaoming Zhang
Xiaomin xiaomin OR xiaoming Zhang
FXFang-Yun Xie
Fang-Yun Xie
Background: The tumor–node–metastasis (TNM) staging system does not perform well for guiding individualized induction or adjuvant chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We attempted to externally validate the Pan's nomogram, developed based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system, for patients with locoregionally advanced disease. In addition, we investigated the reliability of Pan's nomogram for selection of participants in future clinical trials. Methods: This study included 535 patients with locoregionally advanced NPC who were treated between March 2007 and January 2012. The 5‐year overall survival (OS) rates were calculated using the Kaplan–Meier method and compared with predicted outcomes. The calibration was tested using calibration plots and the Hosmer–Lemeshow test. Discrimination ability, which was assessed using the concordance index, as compared with other predictors. Results: Pan's nomogram was observed to underestimate the 5‐year OS of the entire cohort by 8.65% [95% confidence interval (CI) − 9.70 to − 7.60%, P < 0.001] and underestimated the 5‐year OS of each risk group. The differences between the predicted and observed 5‐year OS rates were smallest among low‐risk patients (< 135 points calculated using Pan's nomogram; which predicted minus observed OS, − 6.41%, 95% CI − 6.75 to − 6.07%, P < 0.001) and were largest among high‐risk patients (≥ 160 points) (− 13.56%, 95% CI − 15.48 to − 11.63%, P < 0.001). The Hosmer–Lemeshow test suggested that the predicted and observed 5‐year OS rates had no ideal relationship ( P < 0.001). Pan's nomogram had better discriminatory ability compared with the levels of Epstein–Barr virus DNA acid (EBV DNA) and the 7th or 8th AJCC/UICC staging system, although not better compared with the combination of EBV DNA and the 8th staging system. Additionally, Pan's nomogram was marginally inferior to our predictive model, which included the 8th AJCC/UICC N‐classification, age, gross primary tumor volume, lactate dehydrogenase, and body mass index. Conclusions: Pan's nomogram underestimated the 5‐year OS of patients with locoregionally advanced NPC at our cancer center, and may not be a precise tool for selecting participants for clinical trials.

1 April 2017 in Oral Oncology
Verified
Journal Article
Open access
POPu-Yun OuYang
Pu-Yun OuYang
LZLu-Ning Zhang
Lu-Ning Zhang
YXYao Xiao
Yao Xiao
XLXiao-Wen Lan
Xiao-Wen Lan
XZXiao-Min Zhang
Xiao-Min Zhang
FXFang-Yun Xie
Fang-Yun Xie
We have attempted to validate two published nomograms in nasopharyngeal carcinoma (NPC) and individualize induction chemotherapy (IC) accordingly. From 2007 to 2011, 920 patients were included in the study. The validity of the nomograms was assessed by Harrell's concordance index (C-index), areas under the curve (AUC), and calibration curves. Disease-free survival (DFS) and overall survival (OS) by IC were evaluated in and out of risk stratified patients with and without propensity score matching analysis. Compared with the 7th edition of the Union for International Cancer Control (UICC) staging system, Tang's nomogram better discriminated DFS (C-index 0.629 versus 0.569, P=0.002; AUC 0.635 versus 0.576, P=0.018), whereas Yang's nomogram had no advantage in predicting OS (C-index 0.648 versus 0.606, P=0.184; AUC 0.643 versus 0.604, P=0.157). Calibration curves indicated good agreement between predicted and observed DFS or OS probability. Without risk stratification, patients achieved no benefit from IC in DFS (P⩾0.101) or OS (P⩾0.370). However, among 580 high-risk patients stratified by Tang's nomogram, IC improved five-year DFS from 68.8 to 74.8% (P=0.072), and OS from 82.6 to 87.9% (P=0.065), and the improvement of DFS and OS increased to 9.3% (P=0.019) and 7.3% (P=0.036), respectively, in 426 propensity-matched patients. Tang's nomogram helps to stratify stage III-IVa-b NPC, and IC is beneficial to high-risk patients in clinical practice.